Sectors
Health, BioTech, Industrial
Headquarters
129 N Hill Ave, 103, Pasadena, California 91106, United States
CEO
Jacob Berlin
Terray Therapeutics shares, as of Apr 21, 2025, are valued at a price per share implying an approximate 19.32% premium to their to their last round.Terray Therapeutics shares, as of Apr 21, 2025, are valued at a price per share implying an approximate 19.32% premium to their to their last round.
Register today to view the full report, with more in-depth details and analytics
Series B Valuation
Latest funding round
$401.43M
XXXXX
2024-08-30
XX-XX-XXXX
PM Insights Implied Valuation
$478.98M
2025-04-21
AV Implied Valuation
XXXXX
XX-XX-XXXX
Change since Last Round
+19.32%
2024-08-30 ➞ 2025-04-21
Change since Last Round
XXXXX
XX-XX-XXXX
Secondary Activity
XXXXX
Business Partnerships
Targeted Impact
Who Will Benefit?
What Comes Next?
No items found.
.png)
PM Insights tracks detailed primary funding rounds and verifies cap table directly from original filings for Terray Therapeutics. Terray Therapeutics raised $120.0M in its Series B on August 30, 2024, with a price per share reflecting a post-money valuation of $401.43M, according to PM Insights' market data.
No items found.
No items found.
Ready to see it in action?
Schedule a demo with one of our experts
